U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C16H14N2O3S
Molecular Weight 314.359
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VALDECOXIB

SMILES

CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O

InChI

InChIKey=LNPDTQAFDNKSHK-UHFFFAOYSA-N
InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)

HIDE SMILES / InChI

Molecular Formula C16H14N2O3S
Molecular Weight 314.359
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Valdecoxib was manufactured and marketed under the brand name Bextra. Bextra was indicated for relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis. For the treatment of primary dysmenorrhea. But in 2005 FDA requested that Pfizer withdraw Bextra from the American market, because the Agency had concluded that the overall risk versus benefit profile of Bextra was unfavorable. That conclusion was based on the potential increased risk for serious cardiovascular (CV) adverse events, an increased risk of serious skin reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme) compared to other NSAIDs, and the fact that Bextra had not been shown to offer any unique advantages over the other available NSAIDs.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Dynastat

Approved Use

Dynastat is used for the short-term treatment of pain in adults after an operation.

Launch Date

2002
Palliative
BEXTRA

Approved Use

BEXTRA Tablets are indicated: For relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis. For the treatment of primary dysmenorrhea.

Launch Date

2001
Palliative
BEXTRA

Approved Use

BEXTRA Tablets are indicated: For relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis. For the treatment of primary dysmenorrhea.

Launch Date

2001
Primary
BEXTRA

Approved Use

BEXTRA Tablets are indicated: For relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis. For the treatment of primary dysmenorrhea.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
39.3 ng/mL
1 mg single, intramuscular
dose: 1 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16.8 ng/mL
1 mg single, intramuscular
dose: 1 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
57.9 ng/mL
2 mg single, intramuscular
dose: 2 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
26.4 ng/mL
2 mg single, intramuscular
dose: 2 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
276 ng/mL
5 mg single, intramuscular
dose: 5 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
66.6 ng/mL
5 mg single, intramuscular
dose: 5 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
437 ng/mL
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
130 ng/mL
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1013 ng/mL
20 mg single, intramuscular
dose: 20 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
263 ng/mL
20 mg single, intramuscular
dose: 20 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1681 ng/mL
40 mg single, intramuscular
dose: 40 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
498 ng/mL
40 mg single, intramuscular
dose: 40 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
146 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
284 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
568 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1385 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
161.1 ng/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
14 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.8 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
26 ng/mL
5 mg 2 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
24 ng/mL
10 mg 2 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
26 ng/mL
20 mg 2 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2 ng/mL
5 mg 2 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2 ng/mL
10 mg 2 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2 ng/mL
20 mg 2 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
37.3 ng × h/mL
1 mg single, intramuscular
dose: 1 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
127 ng × h/mL
1 mg single, intramuscular
dose: 1 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
41.9 ng × h/mL
2 mg single, intramuscular
dose: 2 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
258 ng × h/mL
2 mg single, intramuscular
dose: 2 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
130 ng × h/mL
5 mg single, intramuscular
dose: 5 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
563 ng × h/mL
5 mg single, intramuscular
dose: 5 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
275 ng × h/mL
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1133 ng × h/mL
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
579 ng × h/mL
20 mg single, intramuscular
dose: 20 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2782 ng × h/mL
20 mg single, intramuscular
dose: 20 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1167 ng × h/mL
40 mg single, intramuscular
dose: 40 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5215 ng × h/mL
40 mg single, intramuscular
dose: 40 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1787 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3450 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6957 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9062 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1479 ng × h/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
198 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
167 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
175 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
15 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
332 ng × h/mL
5 mg 2 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
341 ng × h/mL
10 mg 2 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
371 ng × h/mL
20 mg 2 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
31 ng × h/mL
5 mg 2 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
33 ng × h/mL
10 mg 2 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
36 ng × h/mL
20 mg 2 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-HYDROXYVALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.36 h
1 mg single, intramuscular
dose: 1 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.83 h
1 mg single, intramuscular
dose: 1 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.43 h
2 mg single, intramuscular
dose: 2 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.28 h
2 mg single, intramuscular
dose: 2 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.25 h
5 mg single, intramuscular
dose: 5 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.67 h
5 mg single, intramuscular
dose: 5 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.41 h
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.44 h
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.48 h
20 mg single, intramuscular
dose: 20 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.94 h
20 mg single, intramuscular
dose: 20 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.87 h
40 mg single, intramuscular
dose: 40 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PARECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
7.35 h
40 mg single, intramuscular
dose: 40 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
8.31 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.53 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.84 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.7 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALDECOXIB serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
8.11 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
PARECOXIB plasma
Homo sapiens
2%
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALDECOXIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-92
Health Status: unhealthy
Age Group: 18-92
Sex: M+F
Sources:
Other AEs: Gastrointestinal ulcer haemorrhage...
Other AEs:
Gastrointestinal ulcer haemorrhage (significant, 0.48%)
Sources:
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy, 32.3 ±10.9
Health Status: unhealthy
Age Group: 32.3 ±10.9
Sex: M+F
Sources:
Disc. AE: Allergic rash, Dizziness...
Other AEs: Dyspepsia, Gastritis...
AEs leading to
discontinuation/dose reduction:
Allergic rash (grade 2, 1%)
Dizziness (grade 2, 1%)
Other AEs:
Dyspepsia (2%)
Gastritis (5.9%)
Sources:
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Disc. AE: Hypertension, Peripheral edema...
AEs leading to
discontinuation/dose reduction:
Hypertension (1.7%)
Peripheral edema (1.7%)
Abdominal pain (2.7%)
Duodenal ulcer (0.2%)
Dyspepsia (2.2%)
Gastric ulcer (1.5%)
Nausea (0.5%)
Vomiting (0.2%)
Rash (1%)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Gastrointestinal perforation, Gastrointestinal ulcer...
Other AEs: Exfoliative dermatitis...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal perforation (grade 3-5)
Gastrointestinal ulcer (grade 3-5)
Gastrointestinal bleeding (grade 3-5)
Other AEs:
Exfoliative dermatitis
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Toxic epidermal necrolysis, Stevens-Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Toxic epidermal necrolysis (grade 3-5)
Stevens-Johnson syndrome (grade 3-5)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Other AEs: Erythema multiforme...
Other AEs:
Erythema multiforme (grade 3-5)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Other AEs: Anaphylactic reaction, Angioedema...
Other AEs:
Anaphylactic reaction
Angioedema
Sources:
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Peripheral edema, Halitosis...
AEs leading to
discontinuation/dose reduction:
Peripheral edema (2.2%)
Halitosis (0.3%)
Abdominal pain (5.5%)
Dyspepsia (6.2%)
Gastroenteritis (1.2%)
Sources:
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Abdominal pain, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (1.6%)
Diarrhea (0.7%)
Dyspepsia (1.4%)
Nausea (0.9%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal ulcer haemorrhage significant, 0.48%
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-92
Health Status: unhealthy
Age Group: 18-92
Sex: M+F
Sources:
Dyspepsia 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy, 32.3 ±10.9
Health Status: unhealthy
Age Group: 32.3 ±10.9
Sex: M+F
Sources:
Gastritis 5.9%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy, 32.3 ±10.9
Health Status: unhealthy
Age Group: 32.3 ±10.9
Sex: M+F
Sources:
Allergic rash grade 2, 1%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy, 32.3 ±10.9
Health Status: unhealthy
Age Group: 32.3 ±10.9
Sex: M+F
Sources:
Dizziness grade 2, 1%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy, 32.3 ±10.9
Health Status: unhealthy
Age Group: 32.3 ±10.9
Sex: M+F
Sources:
Duodenal ulcer 0.2%
Disc. AE
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Vomiting 0.2%
Disc. AE
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Nausea 0.5%
Disc. AE
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Rash 1%
Disc. AE
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Gastric ulcer 1.5%
Disc. AE
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Hypertension 1.7%
Disc. AE
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Peripheral edema 1.7%
Disc. AE
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Dyspepsia 2.2%
Disc. AE
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Abdominal pain 2.7%
Disc. AE
40 mg 2 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy
Exfoliative dermatitis
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Gastrointestinal bleeding grade 3-5
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Gastrointestinal perforation grade 3-5
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Gastrointestinal ulcer grade 3-5
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Stevens-Johnson syndrome grade 3-5
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Toxic epidermal necrolysis grade 3-5
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Erythema multiforme grade 3-5
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Anaphylactic reaction
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Angioedema
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Halitosis 0.3%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Gastroenteritis 1.2%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Peripheral edema 2.2%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Abdominal pain 5.5%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Dyspepsia 6.2%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Diarrhea 0.7%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Nausea 0.9%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Dyspepsia 1.4%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Abdominal pain 1.6%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Parecoxib (parecoxib sodium).
2001
A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model.
2001 Jul
A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects.
2001 Oct
Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
2001 Sep
The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively.
2001 Sep
Cox-2 inhibitors: today and tomorrow.
2002 Apr
Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol.
2002 Jan
[Clinical pharmacology of the selective COX-2 inhibitors].
2003 Dec
The role of cyclooxygenase selective inhibitors in the gastrointestinal tract.
2003 Dec
Efficacy and safety of the first parenteral selective COX-2 inhibitor, parecoxib sodium, in adult patients with postoperative pain.
2003 Jul
Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
2003 Jul
Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.
2003 Jul-Aug
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.
2003 Jun
Clinical pharmacology of selective COX-2 inhibitors.
2003 May-Aug
Stability of reconstituted parecoxib for injection with commonly used diluents.
2003 Oct
Effects of rofecoxib, celecoxib, and parecoxib on anti-IgE-induced histamine release from human skin mast cells and basophils.
2003 Oct
Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery.
2003 Sep
Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension.
2003 Sep
Effect of selective inhibition of cyclooxygenase-2 on lipopolysaccharide-induced hyperalgesia.
2004
Clinical pharmacology of novel selective COX-2 inhibitors.
2004
Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor.
2004 Apr 26
First and second generations of COX-2 selective inhibitors.
2004 Aug
[Review of analgesics].
2004 Dec
Reporting of clinical trials of analgesia.
2004 Feb
Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor.
2004 Feb
S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
2004 Feb 26
Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.
2004 Jul
Early analgesic effects of parecoxib versus ketorolac following laparoscopic sterilization: a randomized controlled trial.
2004 Jun
Parecoxib: a shift in pain management?
2004 Mar
The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans.
2004 Mar
Collision-induced dissociation of valdecoxib metabolites: a novel rearrangement involving an isoxazole ring.
2004 Mar
Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters.
2004 May
A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain.
2004 May
Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
2004 May
Parecoxib for parenteral analgesia in postsurgical patients.
2004 May
Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial.
2004 May
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
2004 May
A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy.
2004 Oct
Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects.
2004 Oct
Parecoxib impairs early tendon repair but improves later remodeling.
2004 Oct-Nov
[Use of low molecular weight heparin (Clexane) together with selective COX-2 inhibitor (Dynastat--once or twice per day)].
2005
Parecoxib: renal failure.
2005 Apr
Cyclooxygenase-2 plays a central role in the genesis of pancreatitis and associated lung injury.
2005 Feb
Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review.
2005 Feb
COX-2 inhibitors--a lesson in unexpected problems.
2005 Mar 17
COX-2 inhibitors--lessons in drug safety.
2005 Mar 17
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
2005 Mar 17
The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist.
2005 May
Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis.
2005 Nov 25
Single dose parecoxib significantly improves ventilatory function in early extubation coronary artery bypass surgery: a prospective randomized double blind placebo controlled trial.
2006 Feb
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: intravenously (IV) or intramuscularly (IM)
The recommended dose is 40 mg administered intravenously (IV) or intramuscularly (IM), followed every 6 to 12 hours by 20 mg or 40 mg as required, not to exceed 80 mg/day.
Route of Administration: Parenteral
100 uM parecoxib inhibited rat osteoclast differentiation by 94%
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:14:41 GMT 2025
Edited
by admin
on Mon Mar 31 18:14:41 GMT 2025
Record UNII
2919279Q3W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BEXTRA
Preferred Name English
VALDECOXIB
EMA EPAR   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
SC-65872
Code English
VALDYN
Brand Name English
VALDECOXIB [MART.]
Common Name English
VALDECOXIB [VANDF]
Common Name English
Valdecoxib [WHO-DD]
Common Name English
VALDECOXIB [MI]
Common Name English
4-(5-METHYL-3-PHENYLISOXAZOL-4-YL)BENZENESULFONAMIDE
Systematic Name English
VALDECOXIB [USAN]
Common Name English
VALDECOXIB [HSDB]
Common Name English
valdecoxib [INN]
Common Name English
VALDECOXIB [EMA EPAR]
Common Name English
P-(5-METHYL-3-PHENYL-4-ISOXAZOLYL)BENZENESULFONAMIDE
Common Name English
VALDECOXIB [ORANGE BOOK]
Common Name English
NSC-759846
Code English
Classification Tree Code System Code
CFR 21 CFR 216.24
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
EMA ASSESSMENT REPORTS VALDYN (WITHDRAWN: ARTHRITIS, RHEUMATOID)
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
WHO-ATC M01AH03
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
EMA ASSESSMENT REPORTS BEXTRA (WITHDRAWN: DYSMENORRHEA)
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
EMA ASSESSMENT REPORTS VALDYN (WITHDRAWN: DYSMENORRHEA)
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
EMA ASSESSMENT REPORTS BEXTRA (WITHDRAWN: OSTEOARTHRITIS)
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
NCI_THESAURUS C1323
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
EMA ASSESSMENT REPORTS VALDYN (WITHDRAWN: OSTEOARTHRITIS)
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
EMA ASSESSMENT REPORTS BEXTRA (WITHDRAWN: ARTHRITIS, RHEUMATOID)
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
WHO-VATC QM01AH03
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
Code System Code Type Description
DRUG BANK
DB00580
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
HSDB
7302
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
MERCK INDEX
m11356
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY Merck Index
DRUG CENTRAL
2799
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
INN
7815
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
NCI_THESAURUS
C1869
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
EVMPD
SUB05065MIG
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
LACTMED
Valdecoxib
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
WIKIPEDIA
VALDECOXIB
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
CHEBI
63634
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
CAS
181695-72-7
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
EPA CompTox
DTXSID6044226
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
USAN
KK-41
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
ChEMBL
CHEMBL865
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
NSC
759846
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
PUBCHEM
119607
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
RXCUI
278567
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY RxNorm
FDA UNII
2919279Q3W
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
SMS_ID
100000085238
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
MESH
C406224
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
IUPHAR
2894
Created by admin on Mon Mar 31 18:14:41 GMT 2025 , Edited by admin on Mon Mar 31 18:14:41 GMT 2025
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
AMOUNT EXCRETED
FECAL; URINE
TARGET -> INHIBITOR
BINDER->LIGAND
Plasma protein binding for valdecoxib is about 98% over the concentration range (21-2384 ng/mL).
BINDING
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
URINE
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE ACTIVE -> PARENT
Plasma concentrations of valdecoxib were 10-20 fold higher than the corresponding SC-66905 (M1) concentrations. The metabolite M1 is a less potent COX-2 specific inhibitor than the parent.
MAJOR
PLASMA
METABOLITE -> PARENT
MINOR
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE ACTIVE -> PARENT
FECAL
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
ORAL BIOAVAILABILITY PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC